GoalVest Advisory’s Gyre Therapeutics GYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$330 Hold
50
﹤0.01% 494
2026
Q1
$349 Buy
+50
New +$388 ﹤0.01% 439

Other funds holding GYRE

GoalVest Advisory's GYRE Position: Q2 2026 in Review

GoalVest Advisory held its Gyre Therapeutics (GYRE) position steady in Q2 2026 at 50 shares worth $330. The position accounts for ﹤0.01% of the portfolio, ranked #494.

GoalVest Advisory first reported a position in GYRE in Q1 2026 and has held it in 2 quarters since. The position peaked at $349 in Q1 2026. 3 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • GoalVest Advisory held 50 shares of Gyre Therapeutics worth $330 as of Q2 2026.
  • GoalVest Advisory left its Gyre Therapeutics share count unchanged in Q2 2026.
  • Gyre Therapeutics made up ﹤0.01% of GoalVest Advisory's portfolio in Q2 2026, its #494 holding.
  • GoalVest Advisory first reported a position in Gyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • GoalVest Advisory's Gyre Therapeutics position peaked at $349 in Q1 2026.
  • 3 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on GoalVest Advisory's 13F filing for Q2 2026, filed 9 Jul 2026.